Larry Kessler, PhD and Ryan Hansen, PhD

Professor, Health Services,
Assistant Professor, Pharmacy,
University of Washington

TITLE: “Cost-Effectiveness Analysis (CEA) in Studies of Treatments for Cystic Fibrosis”

With increasing attention on obtaining value for health in the US health care system, a commonly used tool to evaluate interventions is cost-effectiveness analysis (CEA). Sometimes those findings can create controversy among stakeholders, including patients, clinicians, researchers, and health care systems. For example, on April 27, 2020, the Institute for Clinical and Economic Review (ICER) published a report titled Modulator Treatments for Cystic Fibrosis: Effectiveness and Value. They found a very high cost-effectiveness estimate for the new triple therapy Trikafta. ICER goes on to say, “analyses suggest that the price set by the manufacturer would need to be deeply discounted to align fairly with these benefits and ensure that they are not outweighed by the negative health effects for others resulting from increasing insurance costs.” Why do we perform these analyses? What goes into a cost-effectiveness analysis? What decisions influence such analyses? In this seminar, Ryan Hansen and Larry Kessler will provide a brief introduction to CEA, briefly discuss methods and basic findings of the recent ICER report and use a local example of an ongoing CEA we are doing of the eICE Home Spirometry trial.

ZOOM LINK: https://washington.zoom.us/j/92110910112?pwd=b0ZyQkcwd1JqUHR4ZWV0VU5GL2hFdz09

Download flyer here